anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Silicosis is a systemic disease caused by long-term exposure to high concentrations of free silica dust particles in the workplace. It is characterized by a persistent inflammatory response, fibroblast proliferation, and excessive collagen deposition, leading to pulmonary interstitial fibrosis. Epithelial interstitial transformation (EMT) can cause epithelial cells to lose their tight junctions, cell polarity, and epithelial properties, thereby enhancing the properties of interstitial cells, which can lead to the progression of fibrosis and the formation of scar tissue. Integrin 1 (ITGB1) is considered an important factor for promoting EMT and tumor invasion in a variety of tumors and also plays an important role in the progression of fibrotic diseases. Therefore, ITGB1 can be used as a potential target for the treatment of silicosis. In this study, we found that silica exposure induced epithelial-mesenchymal transformation in rats and that the expression of integrin ITGB1 was elevated along with the EMT. We used CRISPR/Cas9 technology to construct integrin ITGB1 knockdown cell lines for in vitro experiments. We compared the expression of the EMT key proteins E-cadherin and vimentin in the ITGB1 knockdown cells and wild-type cells simultaneously stimulated by silica and detected the aggregation point distribution of E-cadherin and vimentin in the cells using laser confocal microscopy. Our results showed that ITGB1 knockout inhibited the ITGB1/ILK/Snail signaling pathway and attenuated the EMT occurrence compared to control cells. These results suggested that ITGB1 is associated with silica-induced EMT and may be a potential target for the treatment of silicosis.
In Visit 1 subjects tested BD/33G, OTM/33G and ACC/28G devices. In Visit 2 subjects tested BD/33G and ACC/28G. See purpose for additional information.
Compsns. contain diethyl trichloropentyl phosphates of formula: They are used as hypotensive agents in glaucoma; myotics for eye injuries in post-operative treatment and mydriatic antagonists for neutralising medicamental mydriasis. Prepn. is by reaction of EtOH with PCl3 to give diEt-chlorophosphate then reacting this in the presence of pyridine with chloropentyl alcohol. Formulation is as 0.5-2.0% soln. in e.g. olive oil for injection or 5% for eye drops.
Sodium Acetate Injection, USP (2 mEq/mL) is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Using aseptic technique, transfer the desired amount to other intravenous fluids to provide the appropriate number of milliequivalents (mEq) of sodium acetate.

Sodium Acetate Injection, USP (2 mEq/mL) in the Pharmacy Bulk Package is designed for use with manual, gravity flow operations and automated compounding devices for preparing intravenous nutritional admixtures. Admixtures must be stored under refrigeration and used within 24 hours after compounding.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration (See PRECAUTIONS).
Sleep-disordered breathing is a common disease that affects life function and quality of life, and it also imposes a great burden on the public health system. Obstructive sleep apnea accounts for the largest proportion of sleep-disordered breathing, and because of the oriental facial structure, the prevalence of sleep-disordered breathing is relatively high. The current gold standard for diagnosis OSA is polysomnography (PSG). Although the physiological information collected by PSG is complete and detailed, it requires a considerable amount of manpower and medical resources, and changes in the sleep environment also cause bias in the accuracy of inspection. So far, the tools for simple and accurate screening and diagnosis OSA are relatively limited. In this study, TipTraQ, a wearable device developed by PranaQ, was used to collect photoplethysmography (PPG) of patients during the night of PSG inspection. The reliability and validity analysis was carried out by comparing with the corresponding indicators of PSG, and the feasibility of TipTraQ as a tool for home sleep test (HST).
Mitochondrial DNA (mtDNA) has emerged as a pivotal component in understanding the etiology and susceptibility of cancer. A recent study by Chen and colleagues delineated the germline genetic effect of mtDNA single-nucleotide polymorphisms (SNP) and haplogroups across pan-cancer risk. They identified a subset of mtSNPs and the corresponding risk score, as well as haplogroups A and M7 alongside their genetic interactions, conferring a protective effect against various cancers. These findings underscored the value of mtDNA variations as biomarkers for cancer etiology and as tools for cancer risk stratification. Future investigations are encouraged to integrate comprehensive omics data of genomics, transcriptomics, proteomics, and metabolomics, etc., from nuclear DNA with mtDNA variations, alongside single-cell and spatial technologies, to unravel the tumor mechanism and identify the drug targets. Moreover, the incorporation of polygenic risk score, that included mtDNA variations with both rare and common frequencies, and liquid biopsy-based biomarkers would enhance the predictive performance of cancer risk assessment and refine the risk stratification of population-based cancer screening. This commentary advocates for the validation across diverse populations to harness the full potential of mitochondrial genomics, and ultimately paves the prospective way for advancements in personalized cancer therapeutics and prevention strategies. See related article by Chen and colleagues, Cancer Epidemiol Biomarkers Prev 2024;33:381-8.
PROBLEM TO BE SOLVED: To obtain a new compound which inhibits steroid sulfatase activity in vitro and in vivo, and is useful e.g. for the therapy of breast cancer. SOLUTION: This new compound has a ring system such as a steroid ring having three or more rings the two or more of which are condensed, a sulfamate group of formula I [wherein R1 and R2 are each selected from the group consisting of H, a (cyclo)alkyl, an alkenyl and an aryl and at least one of R1 and R2 is H] and a Km value of <50 μM when incubated together with steroid sulfatase enzyme (E.C. 3.1.6.2) at pH 7.4 and 37 deg.C, and is e.g. estrone 3-sulfamate. The compound having the ring system and the sulfamate group of formula I is obtained e.g. by reacting an estrone of formula II with a sulfamoyl chloride of the formula: R1R2NSO2Cl in an inactive organic solvent such as dehydrated dimethylformamide in the presence of sodium hydride. The dose of the compound preferably is in the range of 200-250 mg/day/adult.
An IoT device and system improves on prior approaches to tracking and analyzing symptoms and behavior of special needs individuals. The IoT device may include one or more buttons that can be pressed or held for an extended time by the user. Button presses and duration may be registered in a remote computer as being associated to a symptom or behavior. Patterns may be registered based on a sequence of the button presses and duration. Triggered button events may be collected and transmitted to a host server/network for re-transmission to support team members. In some embodiments, a machine learning module may analyze the collected data for patterns and/or deviations of behavior, which may be displayed to team members. In some embodiments, an automatic prognosis may be generated.
Male sexual health is an often overlooked and ignored facet of mens well-being. However, this can have significant effects on quality of life for both the man afflicted by sexual dysfunction as well as their partner. Most commonly we think of erectile dysfunction (ED) as the main factor of male sexual dysfunction, but ejaculatory dysfunction (EjD) and other problems relating to orgasm are also important. EjD is exceedingly common especially in the aging male population, and includes premature ejaculation (PE), delayed ejaculation (DE), anejaculation (absence of ejaculation during orgasm), retrograde ejaculation, and painful ejaculation. Medications such as sildenafil (Viagra) and tadalafil (Cialis) are Phosphodiesterase type 5 (PDE-5) inhibitors that are commonly used for the treatment of ED, but there are very few medications specifically formulated to treat EjD. More conservative management options for the treatment of ED include vacuum erection devices, psychotherapy, and lifestyle changes. The usual next step after failure of the above options includes intracavernosal injections which involve directly injecting erectogenic medication into the penis, intraurethral injections, or finally surgery. Ejaculatory dysfunction on the other hand, whether it be premature, delayed, retrograde, or anejaculation all have much less treatment options. Most of these include either the off-label use of medications to treat other conditions or sex therapy / psychotherapy.

Treatments including pudendal neuromodulation or pudendal canal decompression have shown significant improvement in ED and EjD. Due to side effects and the lack of patient compliance to oral medication, non-oral medication treatments are in high demand for this condition. Neuromodulation therapies have become increasingly popular for the treatment of male sexual dysfunction. These neuromodulation therapies often work by stimulating the sacral nerve. The Emsella Chair is a conservative neuromodulation therapy that may have a role for patients who are not surgical candidates or who desire a noninvasive treatment option. The Emsella Chair uses high intensity focused electromagnetic (HIFEM) technology to induce deep pelvic floor muscle contractions, the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment awakens deconditioned pelvic floor muscles, delivers the stimulations, and then relaxes the muscles. The repetition of these phases leads to pelvic floor adaptation and remodulation. this treatment could provide similar improvement for men with sexual dysfunction given the significant overlap in anatomy and physiology, as well as studies that have shown improvement in sexual dysfunction with pelvic floor muscle therapy.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Olanzapine and fluoxetine capsules are not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning and Use in Specific Populations (8.5)]. 

In olanzapine placebo-controlled clinical trials of elderly patients with dementia-related psychosis, the incidence of death in olanzapine-treated patients was significantly greater than placebo-treated patients (3.5% vs 1.5%, respectively). 

Meta-Analysis of Antipsychotic Use in Dementia-Related Psychosis – Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Olanzapine and fluoxetine capsules are not approved for the treatment of patients with dementia-related psychosis [see Use in Specific Populations (8.5)].

Cerebrovascular Adverse Events (CVAE), Including Stroke — Cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with olanzapine compared to patients treated with placebo. Olanzapine and olanzapine and fluoxetine capsules are not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning].
BACKGROUND: Dysphagia, particularly sarcopenic dysphagia, is frequent in frail older patients. Sarcopenic dysphagia is a swallowing disorder caused by sarcopenia, corresponding to a loss of muscle mass and strength. It frequently leads to inhalation and to the decrease of food intake, leading the patient to enter a vicious circle of chronic malnutrition and frailty. The awareness of the major health impacts of sarcopenic dysphagia is recent, explaining a low rate of screening in the population at risk. In this context, methods of prevention, evaluation and intervention of sarcopenic dysphagia adapted to the most at-risk population are necessary.
METHODS: The DYSPHAGING (dysphagia & aging) pilot study is a prospective, multicentre, non-comparative study aiming to estimate the feasibility of an intervention on allied health professionals using the DYSPHAGING educational sheet designed to implement a two-step procedure 'screen-prevent' to mitigate swallowing disorders related to sarcopenic dysphagia. After obtaining oral consent, patients are screened using Eating Assessment Tool-10 Score. In case of a score≥2, procedures including positional manoeuvres during mealtimes, food and texture adaptation should be implemented. The primary endpoint of the study is the feasibility of this two-step procedure (screening-prevention measures) in the first 3 days after patient's consent.The study will include 102 patients, with an expected 10% rate of non-analysable patients. Participants will be recruited from acute geriatric wards, rehabilitation centres and long-term care units, with the hypothesis to reach a feasibility rate of 50% and reject a rate lower than 35%.
ETHICS AND DISSEMINATION: The study protocol was approved according to French legislation (CPP Ile-de-France VII) on 15 February 2023. The results of the primary and secondary objectives will be published in peer-reviewed journals.
TRIAL REGISTRATION NUMBER: NCT05734586.
The inventive method relates to the production of a substance having radioprotecting properties. Water solutions of hydroxycarboxilic acids exuded from a natural raw material and contained in said substance are treated with ammonium molibdate. Humic substances can be exuded by treating a humified material with alkaline solutions at standard conditions. Composts, sapropels, moss peat and transition peat, the humus horizon of various soils can be used as the humified material. The humic substances can be produced from oxidised wood lignin by treating it with an oxygen-containing gas in an alkaline medium at a temperature equal to 170±20 °C and a pressure ranging from 1.9 to 2.5 MPa during 1-3 hours, aftercooling the stock, separating a solid phase from the solution and acidulating it till pH=2-3 is obtained. The treatment with the ammonium molibdate is carried out at a temperature of 40±5 °C and can be also carried out by exposing to the action of ultrasound having a radiation power of 40 W/cm2, and a frequency of 22 kHz during 4-8 minutes.
PURPOSE: A peat containing cosmetic composition is provided to have effects on skin diseases and pain relieving by including high content of organic material, fulvic acid, humic acid, or humin. CONSTITUTION: A peat containing cosmetic composition comprises a mixture including cypress powder and rosemary powder for removing offensive flavor. The peat has the average particle size of 1-300 micro meters, the moisture content of 85-95 wt%, and the decomposition rate of 7-9. The average particle size of the cypress powder and rosemary powder is 10-60 micro meters. A cosmetic composition includes 4 ~ 20 parts by weight of the mixture including the cypress powder and the rosemary powder based on 100 parts by weight of the peat. The mixing ratio of the cypress powder to the rosemary powder is 60 : 40 - 95 : 5. The cosmetic composition has the average particle size of 100-250 micro meters, moisture content of 88-93 wt%, decomposition rate of 8-9 based on 100 parts by weight of the peat.
The intervention with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
There is provided a diagnostic tool for use in diagnosing diseases, the tool having a detector for detecting the presence of an array of markers indicative of disease. Also provided is a combination of markers for disease, the combination including at least two markers of the disease. A method of choosing such combinations of markers for a given disease as well as a method for detecting a combination of markers for diagnosing the presence of a disease state or determining a disease stage is also provided. The method includes selectively biopanning sera obtained from a patient to obtain cDNA clones to array for analysis and determining if the markers are present among the cDNA clones present in the disease. Epitopes found using this method are also provided as well as a database incorporating these epitopes. A biochip for detecting the presence of a disease marker in a patient's sera is provided, wherein the biochip has a detector contained within the biochip for detecting disease markers in a patient's sera.
PURPOSE: To provide an oral administration compsn. effective for the treatment of a patient with dermatosis accompanied by itching or inflammatory symptom. CONSTITUTION: The oral administration compsn. contg. the waste granular extract obtd. by extracting the waste grains in a moist or dry state, more preferably in the dry state. The solvent used for the extraction is preferably liquid or supercritical CO2 or NO2 and is more particularly preferably the supercritical CO2 . The extraction conditions at the time of using the supercritical CO2 are preferably a pressure of 75 to 600 bar, more particularly 150 to 350 bar and 31 to 120 deg.C, more particularly preferably 40 to 90 deg.C. The compsn. is orally medicated as the medicinal compsn. in the form of hard gelatin, soft gelatin or microcapsule or as food components for formula diet contg. 30 to 90 wt.%, more preferably 60 to 80 wt.% waste grain extract.  The quantity of the unsatd. fatty acid in the skin and serum is normalized or increased and unsatd. fatty acid/satd. fat oxidation is improved by the administration of the compsn. The dermatoses to which the compsn. is effective include the atopic dermatitis, ichtyosis, eczema prestate, dry eczema, etc.
This is a prospective observational study. 100 patients in one arm scheduled for cardiac surgery will be enrolled. ECG tracings will be obtained when subject is at rest, in supine position, before induction of anesthesia (within 24 hours prior to induction), after induction of general anesthesia, right before emergence from anesthesia (or before transportation to the ICU if the subject remains intubated), and within 24 hours post-operatively; additional ECG readings may be obtained during the surgery if deemed necessary.
FIELD: biotechnology.SUBSTANCE: invention relates to the field of biotechnology. Nucleic acid molecules encoding chimeric antigen receptors (CAR) and expression vectors containing them are proposed. CARs include an extracellular domain that includes IL-13 or its variant that binds to interleukin-13Rα2 (IL13Rα2), a transmembrane region, a costimulating domain, and an intracellular signaling domain. A population of human T- cells expressing CAR targeted IL13Rα2. The human T- cell population contains central memory T- cells. In addition, the invention relates to a composition for the treatment of cancer containing the specified population of T- cells.EFFECT: invention provides improved antitumor efficacy due to improved resistance of T- cells in the tumor micro environment.10 cl, 27 dwg, 5 tbl, 12 ex
Amidated fibrinolytic enzymes are provided which are -COOH-terminal amidated derivatives of human pro-urokinase. These derivatives have the general formula P-CONH2 (I) in which P represents the portion of human pro-urokinase, or a modification thereof, preceding the carboxy terminus. The modifications may be by way of deletion, insertion or substitution. A precursor of such derivatives has the formula P-Gly-Yn (I) wherein Y is any basic amino acid residue and n is 0 or an integer of 1-4. Processes for preparation of formula II via recombinant DNA techniques are detailed. Compounds of formula II provide precursors for in vitro or in vivo enzymatic amidation. Pharmaceutical compositions comprising compounds defined in formula (I) or (II) are provided for the treatment of acute myocardial infarction, pulmonary embolism or deep venous thrombosis.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with high incidence and mortality worldwide. Despite diagnostic and therapeutic advancements, HCC remains poorly responsive to treatment, with a poor prognosis. Understanding the molecular mechanisms driving HCC is crucial for developing effective therapies. Emerging evidence indicates that dysregulated fatty acid metabolism contributes to HCC. Acyl-CoA medium-chain synthetase 5 (ACSM5), involved in fatty acid metabolism, is down-regulated in HCC; however, its role is not well understood. This study was used to analyze ACSM5 expression in HCC patient samples and cell lines. The newly established ACSM5-overexpressing HCC cell lines, Huh7-ACSM5 and Hepa1-6-ACSM5, were used to investigate the effects and regulatory mechanisms of ACSM5. The results showed that ACSM5 was significantly down-regulated in HCC tumor tissues compared with non-tumor tissues. ACSM5 expression was regulated by DNA methylation, with a DNA methyltransferase 1 (DNMT1) inhibitor effectively increasing ACSM5 expression and reducing promoter region methylation. Overexpression of ACSM5 in Huh7 cells reduced fatty acid accumulation, decreased cell proliferation, migration, and invasion in vitro, and inhibited tumor growth in mouse xenografts. Furthermore, ACSM5 overexpression also decreased STAT3 phosphorylation, subsequently affecting downstream cytokine TGFB and FGF12 mRNA levels. These findings suggest that ACSM5 down-regulation contributes to HCC progression, providing insights into its oncogenic role and highlighting its potential as a biomarker and therapeutic target for HCC.
Patients receive the supervised exercise intervention over 8 weeks on study. Patients also undergo collection of blood samples at baseline and week 8.
FIELD: medicine, in particular, medical cosmetology. SUBSTANCE: cream containing natural bee wax, stabilizer, fat and water phases, additionally has mumiyo (biologically active product). Used as a stabilizer is concentrate of biologically active components of isoprenoid and phenylpropanoid row separated from propolis at the following ratio of components, mas.%: natural bee wax, 2-15; mumiyo, 0.05-0.3; concentrate of biologically active components separated from propolis, 0.1-3.0; fat phase, 40-60; water phase, the balance. Used as fat phase are natural vegetable and/or animal oils. Cream accelerates process of healing of osseous tissues till their full restoration, favorably affects at varicosis and thrombophlebitis, assists resolution of gouty pinea. EFFECT: higher efficiency. 2 cl
Participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent using an existing secure text messaging platform.